AVBP ArriVent BioPharma, Inc.
$15.36▼ -26.86%
Healthcare
Other
Volume 5.95M
Avg Volume (10D) 1.91M
Key Metrics & Fundamentals
Market Cap
$757.37M
P/E Ratio
–
Div Yield
0.00%
52W Range
11.36 - 35.83
% vs 50 MA
-40.65%
% vs 200 MA
-43.26%
RSI-14
32.1
MACD Histogram
+0.2700
Beta (1Y vs SPY)
0.82
Free Cash Flow
-$39.58M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$52.69M
COGS
–
Operating Exp
$52.69M
Operating Income
-$52.69M
EBIT
-$52.69M
Pretax Income
-$49.89M
Net Income
-$49.89M
EPS (Diluted)
-1.05
Price & Volume History
Loading chart…
Recent News
ArriVent BioPharma’s ARR-217 Shows 44.8% Response Rate in Colorectal Cancer Study
MarketBeat · Oct 27, 2026 12:02 AM ET
ArriVent BioPharma (AVBP) Advances ARR 217 Into Phase 1b, Is The Selloff Overdone?
Simply Wall St. · Oct 26, 2026 9:08 PM ET
ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026
GlobeNewswire · Oct 25, 2026 9:00 AM ET
Why ArriVent BioPharma Stock Is In Focus After Trial Failure And Legal Probe
Simply Wall St. · Oct 24, 2026 8:14 AM ET
ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026
GlobeNewswire · Oct 23, 2026 4:00 PM ET
ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer
GlobeNewswire · Oct 19, 2026 8:01 AM ET
ArriVent BioPharma Doses First Patient in Phase 1 Trial of ARR-002 for Ovarian, Endometrial Cancer
MT Newswires · Oct 12, 2026 4:58 PM ET
ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
GlobeNewswire · Oct 12, 2026 4:01 PM ET
Shanghai Allist shares slide after U.S. partner’s lung cancer drug trial fails
Investing.com · Oct 8, 2026 1:38 AM ET
ArriVent’s stock plummets on Phase III NSCLC trial failure
Clinical Trials Arena · Oct 7, 2026 10:50 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See AVBP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.